Ocuphire Pharma is a clinical-stage company that develops therapies for refractive and retinal eye disorders, headquartered in Farmington Hills, Michigan. Their lead product candidate is Nyxol eye drops, which is in Phase III clinical trial for dim light or night vision disturbances, Phase 2b clinical trial for pharmacologically induced mydriasis, and Phase 2 VEGA-1 trial for presbyopia. They also develop other product candidates to target pathways relevant to retinal and choroidal vascular diseases.